The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Alvotech (“Alvotech” or the “Company”) (NASDAQ: ALVO) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

[LEARN MORE ABOUT THE INVESTIGATION]

What Happened?

On November 3, 2025, the Company received a complete response letter (“CRL”) from the FDA for its biologics license application for AVT05. The CRL relates to a failed facility inspection which occurred in July 2025. On this news, the price of Alvotech shares declined by $2.62 per share, or approximately 34.25%, from $7.65 per share on October 31, 2025 to close at $5.03 on November 3, 2025.

What Should I Do?

If you purchased or otherwise acquired Alvotech securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251119389606/en/